Effects of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, on Perceived Stress and Cognitive Function Among Patients With Late-Life Depression: A Randomized, Double-Blind, Sertraline- and Placebo-Controlled Trial

Chieh-Hsin Lin, Shi-Heng Wang, Hsien-Yuan Lane, Chieh-Hsin Lin, Shi-Heng Wang, Hsien-Yuan Lane

Abstract

Background: Compared with adults with depression in the general population, elderly depressive patients are prone to poor treatment response, more side effects, and early withdrawal with current antidepressants (which principally modulate monoamines). Whether N-methyl-D-aspartate receptor enhancement can benefit treatment of late-life depression deserves study. This study aims to compare sodium benzoate (a D-amino acid oxidase inhibitor and an indirect N-methyl-D-aspartate receptor enhancer), sertraline (a selective serotonin reuptake inhibitor), and placebo in the treatment of late-life depression.

Methods: In this randomized, double-blind trial, 117 patients with major depressive disorder aged 55 years or older received 8-week treatment of 250-1500 mg/d of sodium benzoate, 25-150 mg/d of sertraline, or placebo in 2 medical centers. The primary outcome measures were Hamilton Depression Rating Scale and Perceived Stress Scale scores.

Results: Three treatments similarly decreased clinicians-rated Hamilton Depression Rating Scale scores. Compared with placebo, sodium benzoate but not sertraline substantially improved Perceived Stress Scale scores and cognitive function. Sertraline, but not benzoate, significantly reduced self-report Geriatric Depression Scale scores. Benzoate and placebo showed similar safety profiles, while sertraline was more likely to raise low-density lipoprotein than benzoate and placebo. Benzoate-treated patients were less likely to drop out than sertraline or placebo recipients.

Conclusions: Sertraline can reduce subjective depressive symptoms, while benzoate can decrease perceived stress, improve cognitive function, and enhance treatment adherence in late-life depression patients. The results show promise for D-amino acid oxidase inhibition as a novel approach for perceived stress and cognitive decline among patients with late-life depression.

Trial registration: ClinicalTrials.gov Identifier: NCT03414931. Registered January 2016.

Keywords: Cognition; N-methyl-D-aspartate; late; life depression; perceive stress; sodium benzoate.

© The Author(s) 2022. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
Flow diagram and disposition of the 3 treatment groups.

References

    1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th ed.Washington, DC: American Psychiatric Press.
    1. Aizenstein HJ, Butters MA, Wu M, Mazurkewicz LM, Stenger VA, Gianaros PJ, Becker JT, Reynolds CF 3rd, Carter CS (2009) Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry 17:30–42.
    1. Alexopoulos GS (2019) Mechanisms and treatment of late-life depression. Transl Psychiatry 9:188.
    1. Banerjee S, et al. (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403–411.
    1. Banjongrewadee M, Wongpakaran N, Wongpakaran T, Pipanmekaporn T, Punjasawadwong Y, Mueankwan S (2020) The role of perceived stress and cognitive function on the relationship between neuroticism and depression among the elderly: a structural equation model approach. BMC Psychiatry 20:25.
    1. Beck AT, Kovacs M, Weissman A (1979) Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol 47:343–352.
    1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354.
    1. Bickford D, Morin RT, Nelson JC, Mackin RS (2020) Determinants of suicide-related ideation in late life depression: associations with perceived stress. Clin Gerontol 43:37–45.
    1. Brahmachari S, Jana A, Pahan K (2009) Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 183:5917–5927.
    1. Burket JA, Pickle JC, Rusk AM, Haynes BA, Sharp JA, Deutsch SI (2020) Glycine transporter type 1 (GlyT1) inhibition improves conspecific-provoked immobility in BALB/c mice: analysis of corticosterone response and glucocorticoid gene expression in cortex and hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 99:109869.
    1. Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG, Reynolds CF 3rd (2000) Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 157:1949–1954.
    1. Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, Zmuda MD, Bhalla R, Meltzer CC, Pollock BG, Reynolds CF 3rd, Becker JT (2004) The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry 61:587–595.
    1. Casaletto KB, Staffaroni AM, Elahi F, Fox E, Crittenden PA, You M, Neuhaus J, Glymour M, Bettcher BM, Yaffe K, Kramer JH (2018) Perceived stress is associated with accelerated monocyte/macrophage aging trajectories in clinically normal adults. Am J Geriatr Psychiatry 26:952–963.
    1. Chang CH, Lane HY, Tseng PT, Chen SJ, Liu CY, Lin CH (2019) Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol 33:436–448.
    1. Chávez-Castillo MO, Nava M, Fuenmayor J, Lameda V, Velasco M, Bermúdez V, Rojas-Quintero J (2018) Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable? Vessel Plus 2:6.
    1. Chen KT, Tsai MH, Wu CH, Jou MJ, Wei IH, Huang CC (2015) AMPA receptor-mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of AMPA receptor may play a role. Front Behav Neurosci 9:162.
    1. Chong MY, Tsang HY, Chen CS, Tang TC, Chen CC, Yeh TL, Lee YH, Lo HY (2001) Community study of depression in old age in Taiwan: prevalence, life events and socio-demographic correlates. Br J Psychiatry 178:29–35.
    1. Cohen S, Kamarck T, Mermelstein R (1983) A global measure of perceived stress. J Health Soc Behav 24:385–396.
    1. Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, de Mendonça Lima CA, Livingston G (2011) A systematic review of treatments for refractory depression in older people. Am J Psychiatry 168:681–688.
    1. Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, Lobo A, Magnusson H, Mann AH, Meller I, Prince MJ, Reischies F, Turrina C, deVries MW, Wilson KC (1999) Depression in Europe. Geographical distribution among older people. Br J Psychiatry 174:312–321.
    1. Deng Y, McQuoid DR, Potter GG, Steffens DC, Albert K, Riddle M, Beyer JL, Taylor WD (2018) Predictors of recurrence in remitted late-life depression. Depress Anxiety 35:658–667.
    1. Devanand DP, Pelton GH, Marston K, Camacho Y, Roose SP, Stern Y, Sackeim HA (2003) Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry 18:123–130.
    1. Dong C, Zhang JC, Ren Q, Ma M, Qu Y, Zhang K, Yao W, Ishima T, Mori H, Hashimoto K (2018) Deletion of serine racemase confers D-serine-dependent resilience to chronic social defeat stress. Neurochem Int 116:43–51.
    1. Fjukstad KK, Engum A, Lydersen S, Dieset I, Steen NE, Andreassen OA, Spigset O (2016) Metabolic abnormalities related to treatment with selective serotonin reuptake inhibitors in patients with schizophrenia or bipolar disorder. J Clin Psychopharmacol 36:615–620.
    1. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198.
    1. George D, Gálvez V, Martin D, Kumar D, Leyden J, Hadzi-Pavlovic D, Harper S, Brodaty H, Glue P, Taylor R, Mitchell PB, Loo CK (2017) Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatr Psychiatry 25:1199–1209.
    1. Guercio GD, Panizzutti R (2018) Potential and challenges for the clinical use of d-serine as a cognitive enhancer. Front Psychiatry 9:14.
    1. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health, pp. 217–222.
    1. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
    1. Harrison PJ (2018) D-amino acid oxidase inhibition: a new glutamate twist for clozapine augmentation in schizophrenia? Biol Psychiatry 84:396–398.
    1. Hashimoto K (2020) Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol 177:113935.
    1. Herran A, Ramírez ML, Carrera M, García-Unzueta MT, Sierra-Biddle D, Rodríguez-Cabo B, Ayestarán A, Hoyuela F, Vázquez-Barquero JL (2006) Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol 26:538–540.
    1. Hsieh MT, Lane HY, Lin CH (2019) The role of N-methyl-D-aspartate receptor on late-life depression. Int J Gerontol 13:268–272.
    1. Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY, Tsai GE (2013) Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 74:734–741.
    1. Huang YJ, Lane HY, Lin CH (2017) New treatment strategies of depression: based on mechanisms related to neuroplasticity. Neural Plast 2017:4605971.
    1. Jain S, Mills PJ, von Känel R, Hong S, Dimsdale JE (2007) Effects of perceived stress and uplifts on inflammation and coagulability. Psychophysiology 44:154–160.
    1. Keller A, Litzelman K, Wisk LE, Maddox T, Cheng ER, Creswell PD, Witt WP (2012) Does the perception that stress affects health matter? The association with health and mortality. Health Psychol 31:677–684.
    1. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM, Shea T (1992) Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:809–816.
    1. Kok RM, Nolen WA, Heeren TJ (2012) Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord 141:103–115.
    1. Kok RM, Reynolds CF 3rd (2017) Management of depression in older adults: a review. JAMA 317:2114–2122.
    1. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214.
    1. Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS (2019) Ketamine: a paradigm shift for depression research and treatment. Neuron 101:774–778.
    1. Lai CH, Lane HY, Tsai GE (2012) Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naïve patient with major depression. Biol Psychiatry 71:e9–e10.
    1. Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE (2013) Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 70:1267–1275.
    1. Lane HY, Tu CH, Lin WC, Lin CH (2021) Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial. Int J Neuropsychopharmacol 24:392–399.
    1. Levin R, Dor-Abarbanel AE, Edelman S, Durrant AR, Hashimoto K, Javitt DC, Heresco-Levy U (2015) Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings. J Psychiatr Res 61:188–195.
    1. Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, Lane HY (2014a) Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 75:678–685.
    1. Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, Lane HY (2018) Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 84:422–432.
    1. Lin CH, Chen PK, Wang SH, Lane HY (2019) Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): a randomized, double-blind, placebo-controlled, 6-week trial. J Psychopharmacol 33:1030–1033.
    1. Lin CH, Yang HT, Chen PK, Wang SH, Lane HY (2020) Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD). Neuropsychiatr Dis Treat 16:509–518.
    1. Lin CH, Chen PK, Wang SH, Lane HY (2021) Effect of sodium benzoate on cognitive function among patients with behavioral and psychological symptoms of dementia: secondary analysis of a randomized clinical trial. JAMA Netw Open 4:e216156.
    1. Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY (2017) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry 18:357–368.
    1. Lin JH, Huang MW, Wang DW, Chen YM, Lin CS, Tang YJ, Yang SH, Lane HY (2014b) Late-life depression and quality of life in a geriatric evaluation and management unit: an exploratory study. BMC Geriatr 14:77.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100.
    1. Lipsitz O, Di Vincenzo JD, Rodrigues NB, Cha DS, Lee Y, Greenberg D, Teopiz KM, Ho RC, Cao B, Lin K, Subramaniapillai M, Flint AJ, Kratiuk K, McIntyre RS, Rosenblat JD (2021) Safety, tolerability, and real-world effectiveness of intravenous ketamine in older adults with treatment-resistant depression: a case series. Am J Geriatr Psychiatry 29:899–913.
    1. Mathews DC, Henter ID, Zarate CA (2012) Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72:1313–1333.
    1. Mecocci P, Cherubini A, Mariani E, Ruggiero C, Senin U (2004) Depression in the elderly: new concepts and therapeutic approaches. Aging Clin Exp Res 16:176–189.
    1. Miu DK, Chan CK (2011) Prognostic value of depressive symptoms on mortality, morbidity and nursing home admission in older people. Geriatr Gerontol Int 11:174–179.
    1. Morimoto SS, Alexopoulos GS (2013) Cognitive deficits in geriatric depression: clinical correlates and implications for current and future treatment. Psychiatr Clin North Am 36:517–531.
    1. Nebes RD, Pollock BG, Houck PR, Butters MA, Mulsant BH, Zmuda MD, Reynolds CF 3rd (2003) Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res 37:99–108.
    1. O’Neal WT, Qureshi W, Judd SE, Glasser SP, Ghazi L, Pulley L, Howard VJ, Howard G, Soliman EZ (2015) Perceived stress and atrial fibrillation: the reasons for geographic and racial differences in stroke study. Ann Behav Med 49:802–808.
    1. Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD (2020) Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun 87:901–909.
    1. Osmanovic-Thunstrom A, Mossello E, Åkerstedt T, Fratiglioni L, Wang HX (2015) Do levels of perceived stress increase with increasing age after age 65? A population-based study. Age Ageing 44:828–834.
    1. Payne C, Hedberg EC, Kozloski M, Dale W, McClintock MK (2014) Using and interpreting mental health measures in the National Social Life, Health, and Aging Project. J Gerontol B Psychol Sci Soc Sci 69 Suppl 2:S99–S116.
    1. Pizzagalli DA, Bogdan R, Ratner KG, Jahn AL (2007) Increased perceived stress is associated with blunted hedonic capacity: potential implications for depression research. Behav Res Ther 45:2742–2753.
    1. Raeder MB, Bjelland I, Emil Vollset S, Steen VM (2006) Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 67:1974–1982.
    1. Riihimaki KA, Vuorilehto MS, Melartin TK, Isometsä ET (2014) Five-year outcome of major depressive disorder in primary health care. Psychol Med 44:1369–1379.
    1. Rueggeberg R, Wrosch C, Miller GE (2012) The different roles of perceived stress in the association between older adults’ physical activity and physical health. Health Psychol 31:164–171.
    1. Salazar-Villanea M, Liebmann E, Garnier-Villarreal M, Montenegro-Montenegro E, Johnson DK (2015) Depressive symptoms affect working memory in healthy older adult Hispanics. J Depress Anxiety 4:204.
    1. Sheikh JI, Yesavage JA (1986) Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 5:165–173.
    1. Steffens DC, Skoog I, Norton MC, Hart AD, Tschanz JT, Plassman BL, Wyse BW, Welsh-Bohmer KA, Breitner JC (2000) Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 57:601–607.
    1. Taylor WD (2014) Clinical practice. Depression in the elderly. N Engl J Med 371:1228–1236.
    1. Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI (2011) Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 72:1660–1668.
    1. Turner EH (2019) Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. Lancet Psychiatry 6:977–979.
    1. Vasunilashorn S, Glei DA, Weinstein M, Goldman N (2013) Perceived stress and mortality in a Taiwanese older adult population. Stress 16:600–606.
    1. Wechsler D (1991) Wechsler intelligence scale for children. 3rd ed.San Antonio, TX: Psychological Association.
    1. Wechsler D (1997) Wechsler memory scale. 3rd ed.San Antonio, TX: Psychological Association.
    1. Wei F, Crain AL, Whitebird RR, Godlevsky OV, O’Connor PJ (2009) Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs 23:857–865.
    1. Wei IH, Chen KT, Tsai MH, Wu CH, Lane HY, Huang CC (2017) Acute amino acid d-serine administration, similar to ketamine, produces antidepressant-like effects through identical mechanisms. J Agric Food Chem 65:10792–10803.
    1. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Hashimoto K (2017) Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis. Transl Psychiatry 7:e1138.
    1. Zivin K, Kales HC (2008) Adherence to depression treatment in older adults: a narrative review. Drugs Aging 25:559–571.
    1. Zou B, Miao C, Chen J (2020) Depression and perceived stress, but not anxiety, are associated with elevated inflammation in an obese adult population. Risk Manag Healthc Policy 13:1489–1497.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅